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family of transcription factors. Transformation by v-Rel is mediated by the aberrant expression of genes that
are normally regulated by Rel/NF-κB. Here, we demonstrate activation of the TGF-β/Smad signaling pathway
in Rel transformation. RNA and protein levels of key TGF-β and Smad family members (TGF-β2, -β3, TGF-β
type II receptor, and Smad3) are upregulated in v-Rel transformed cells with little to no change in c-Rel-
expressing cells. Treatment of v-Rel transformed lymphoid cells with kinase inhibitors of the TGF-β receptor
dramatically reduces soft agar colony formation whereas addition of TGF-β2 further promotes transforma-
tion. Moreover, Smad3 but not Smad2, is selectively activated as the downstreammediator of TGF-β signaling.
Blocking Smad3 expression or activity inhibits the oncogenic potential of v-Rel. Overall, TGF-β/Smad signaling
is activated at multiple levels and is required for the transforming ability of v-Rel.ent of Molecular Genetics and
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The Rel/NF-κB family of transcription factors plays important roles
in immune and inﬂammatory responses, proliferation, and apoptosis
(Aggarwal, 2004; Bonizzi and Karin, 2004). Rel/NF-κB complexes
regulate the expression of a wide range of target genes through
speciﬁc decameric DNA sites (κB sites) (Chen and Ghosh, 1999).
Elevated expression of Rel/NF-κB proteins and/or disruption in their
regulation has been implicated in hematopoietic cancers and solid
tumors (Karin et al., 2002; Luque and Gelinas, 1997). The earliest
evidence of a role for Rel/NF-κB in oncogenic cell transformation came
from studies with v-Rel. v-Rel is derived from the transduction of
turkey c-rel sequences into the avian reticuloendotheliosis-associated
retrovirus (REV-A) (Gilmore, 1999). While c-rel is weakly oncogenic,
v-rel is the most efﬁciently transforming member of the Rel/NF-κB
family of transcription factors. Having acquired multiple mutations,
v-Rel exhibits altered DNA binding speciﬁcity and transactivation
potential and is able to escape negative regulation (Hrdlickova et al.,
1995; Kabrun et al., 1991; Sachdev and Hannink, 1998). Viruses
expressing v-Rel induce avian and mammalian lymphoid cell tumorsand, in culture, can immortalize primary splenic lymphocytes (Liss
and Bose, 2008). v-Rel also transforms chicken embryonic ﬁbroblasts
in vitro and induces sarcomas in experimentally infected chickens.
Transformation by v-Rel occurs through the inappropriate activation
or repression of genes which are normally regulated by Rel/NF-κB
family members (Gilmore, 1999). In this report, we have identiﬁed
speciﬁc members of the TGF-β/Smad pathway which are upregulated
in v-Rel transformed cells and have found their activation to be critical
to the v-Rel transformation process.
The transforming growth factor-β (TGF-β) proteins are members
of a large family of cytokines that regulate pivotal biological functions,
including cell growth, differentiation, apoptosis, and development
(Rahimi and Leof, 2007; ten Dijke and Hill, 2004). Signaling by TGF-β
is transmitted to the cell interior through TGF-β receptors. Stimulated
by ligand binding, the TGF-β type II receptor (TβIIR) forms a
heteromeric complex with the TGF-β type I receptor (TβIR) and
phosphorylates the TβIR. Phosphorylation of TβIR relieves its
autoinhibition and activates its catalytic kinase domain. This allows
TβIR to then phosphorylate Smad2 and Smad3, the canonical TGF-β
effector molecules (Abdollah et al., 1997; Macias-Silva et al., 1996).
Smad2 and Smad3 phosphorylation triggers their activation, enabling
these Smad proteins to form heteromeric complexes with the
common mediator Smad4 protein (Correia et al., 2001; Kawabata et
al., 1998). These complexes translocate to the nucleus to regulate gene
expression in a cell type-speciﬁc and ligand dose-dependent manner.
TGF-β signalinghas receivedgrowing attention in recentyears due to
its complex role in different cancers, including breast, lung, colon, and
skin cancer, as well as cancers of hematopoietic origin (de Jonge et al.,
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1997; Lange et al., 1999; Takaku et al., 1999; Xu et al., 2000). TGF-β
signaling in theearly stages of oncogenesis has tumor suppressive effects
characterized by antiproliferative activity and induction of apoptosis. In
the later stages, cancer cells gain advantage by selective inactivation of
tumor suppressor activities of TGF-β while retaining the tumor
promoting activities (Massague, 2008). Ultimately, whether TGF-β
signaling incurs an oncogenic or tumor suppressive outcome depends
on its context-speciﬁc effects on cellular targets.
TGF-β/Smad signaling frequently promotes cancers in cooperation
with other transcription factors or through crosstalk with other
signaling pathways (Derynck and Zhang, 2003). While numerous
studies have analyzed how TGF-β/Smads inﬂuence epithelial cell
growth and cancer, less is known about their role in malignancies of
lymphoid origin. Here, we demonstrate the role of TGF-β/Smad
signaling in Rel/NF-κB-mediated transformation, which has not been
previously addressed. Our studies reveal that unlike c-Rel, v-Rel
efﬁciently induces the mRNA and protein expression of TGF-β and
Smad family members, speciﬁcally TGF-β2, TGF-β3, TβIIR, and Smad3.
Furthermore, activation of TGF-β signaling and Smad3, but not
Smad2, is crucial for the transforming ability of v-Rel. Our results
demonstrate that v-Rel activates the TGF-β pathway at multiple levels
to achieve its oncogenic potential.
Results
v-Rel alters the expression of TGF-β and Smad family members
We recently employed microarray technology to identify global
changes in gene expression in v-Rel transformed chicken embryonic
ﬁbroblasts (CEFs) and DT40 cells, a chicken B cell line (manuscript in
preparation). Results from the microarrays identiﬁed four genes from
the TGF-β/Smad pathwaywith at least a 1.6-fold increase in expression
in v-Rel transformed cells. These geneswere tgf-β2, tgf-β3, TGF-β type II
receptor (tgfbr2), and smad3. To corroborate these results, Northern
blot analysis was carried out to evaluate the ability of v-Rel to alter the
expression of all three TGF-β isoforms (tgf-β1–3), the TGF-β receptors,
and smad2, 3, and 4. Total RNA was harvested from CEFs and DT40
cultures infectedwithREV-based retroviruses expressing c-Rel (REV-C)
or v-Rel (REV-TW) or with the helper virus CSV as a control. Consistent
with our microarray results, the expression of tgf-β2, tgf-β3, tgfbr2, and
smad3was elevated in v-Rel transformed CEFs and DT40 cells (Fig. 1A).
While the levels of smad4 were increased in v-Rel transformed DT40
cells, therewas little change observed in CEFs. The altered expression of
members of this pathway was selective as the levels of tgf-β1, TGF-β
type I receptor (tgfbr1), and smad2 were not signiﬁcantly altered in
either ﬁbroblast or lymphoid cell types. The overexpression of c-Rel
also resulted in elevated levels of tgf-β2 (DT40), tgf-β3 (DT40), tgfbr2
(CEFs and DT40), and smad3 (DT40). However, these changeswere less
dramatic than those in cells expressing v-Rel. Real-time PCR analysis
was also performed using cDNA prepared from RNA infected with the
retroviruses described above to quantify the expression of select genes
upregulated in the TGF-β/Smad signaling pathway (tgf-β2, smad3, and
smad2). In agreement with the Northern blot results, tgf-β2 and smad3
expression was dramatically increased in both CEFs and DT40 cells
expressing v-Rel relative to control (Fig. 1B). By contrast, smad2
expression was not signiﬁcantly changed in v-Rel-transformed cells
compared to CSV control. These results demonstrate the ability of v-Rel
to effectively induce the expression of speciﬁc members of the TGF-β
signaling cascade in different cell types.
A temperature-sensitive (ts) v-Rel cell line was used to evaluate
whether TGF-β2 and the Smad proteins might represent direct v-Rel
targets. The ts v-Rel mutant has impaired DNA binding activity at the
non-permissive temperature, resulting in a rapid loss of the
transformed phenotype (White and Gilmore, 1993). Total RNA was
isolated from separate cultures of cells grown at the permissivetemperature (36 °C) and from those shifted to the non-permissive
temperature (41 °C) at zero, two, and six hour time points. Northern
blot analysis revealed that while smad3 expression was not
signiﬁcantly changed at the permissive temperature, its expression
was dramatically reduced as early as 2 h after the shift to the non-
permissive temperature (Fig. 1C). The expression of tgf-β2 was also
downregulated upon shift to the non-permissive temperature,
although less dramatically compared to smad3. The expression of
smad2 remained unaltered at the non-permissive temperature. These
results suggest that Smad3 may be a direct target of v-Rel.
To determinewhether increased expression of smad3 is speciﬁc to
the v-Rel transformation pathway, RNA levels of smad3 were also
analyzed in a panel of lymphoid cell lines transformed by v-Rel and
other avian retroviruses (Fig. S1). Northern blot analysis revealed
that expression of smad3was strongly elevated (from 2.5 to 6.7 fold)
in v-Rel-transformed cells compared to those transformed by other
oncogenes, which either failed to upregulate smad3 expression or did
so less effectively (1.8 fold). These results suggest that smad3 is
consistently upregulated and highly expressed in v-Rel-transformed
cells relative to cell lines transformed by other oncogenes.
The total protein levels of TGF-β and Smad family members which
demonstrated upregulated gene expression were also determined.
ELISAs were performed to analyze the levels of active TGF-β2 ligand
expressed in v-Rel transformed cells. CEFs and DT40 cells were
infected with retroviruses described above, and culture media was
harvested over the course of 10–14 days following infection.
Consistent with the Northern blot results, v-Rel-transformed cells
secreted signiﬁcantly higher levels of TGF-β2 than control cells
(Fig. 2A). In a representative result from one of three experiments,
DT40 cells expressing v-Rel produced approximately 1.7–2.6 fold
more TGF-β2 than control cells (Fig. 2A, left panel). In v-Rel
transformed CEFs, the levels of TGF-β2 produced in the initial three
days after infection were three-fold greater than control cells (Fig. 2A,
right panel). Over later time points, a 9–16 fold increase in TGF-β2
levels was observed as CEFs expressing v-Rel becamemorphologically
transformed. c-Rel induced a 2.5–3.5 fold increase (CEFs) or minimal
change (DT40) in TGF-β2 compared to control cells.
To analyze the protein levels of the remaining TGF-β signaling
components with upregulated RNA expression, Western blot analysis
was performedonwhole cell lysates isolated fromthe infectedCEFs and
DT40 cells described above. v-Rel expression increased the levels of the
TGF-β type II receptor protein (TβIIR) and Smad3 in both CEFs and
DT40 cells (Fig. 2B). Since the TGF-β-dependent activation of Smad3
occurs by the phosphorylation of Ser423 and Ser425 (Attisano and
Wrana, 1998), we evaluated whether the phosphorylation status of
these sites was affected in v-Rel transformed cells. Consistent with the
elevated expression of TβIIR and TGF-β2, the levels of phosphorylated
Smad3 were found to be higher in v-Rel-expressing CEFs and DT40
cells. Meanwhile, total Smad2 levels remained unaltered in both cell
types, corresponding to its RNA levels. The levels of phosphorylated
Smad2 were, however, upregulated in DT40 cells and CEFs. This
indicated that, although v-Rel transformed cells do not upregulate total
Smad2RNAandproteins levels, TGF-β2 signaling in these cells is able to
activate Smad2. The overexpression of c-Rel modestly raised the levels
of TβIIR and total and phospho-Smad3, revealing differences in the
ability of v-Rel and c-Rel to upregulate the TGF-β/Smadpathway. These
results indicate that v-Rel selectively increases the RNA and protein
levels of key TGF-β signaling components relative to c-Rel, which is
weakly oncogenic.
The TGF-β signaling pathway increases Smad3 activation in v-Rel
transformed cells
Key components of the TGF-β pathway have been shown to be
inactivated in immortalized or transformed cell lines to achieve
oncogenic potential (de Caestecker et al., 2000; de Jonge et al., 1997;
Fig. 1. Expression of mRNAs encoding TGF-β and Smad family members in Rel transformed cells. (A) DT40 cells and CEFs were infected with CSV helper virus (H), or viruses
expressing c-Rel (C) or v-Rel (V). Total RNA (10 μg) was harvested for Northern blot analysis to determine mRNA expression of key components of the TGF-β/Smad signaling
pathway. (B) Real-time PCR was performed to analyze relative mRNA levels of smad2, smad3, and tgf-β2 using cDNA synthesized from DT40 cells and CEFs infected with viruses
described in (A). The mRNA expression for each gene was normalized to GAPDH values (Ct), and the extent of upregulation of each gene was compared against the CSV control
samples (ΔΔCt). (C) Cultures of a temperature-sensitive v-Rel cell line were grown in parallel at 36 °C and at 41 °C for 0, 2, and 6 h after the shift to the non-permissive temperature.
Total RNA (10 μg) harvested from cells was subjected to Northern blot analysis to examine smad2, smad3, and tgf-β2 levels. As an internal control, v-rel expression is shown to be
unaltered at both the permissive and non-permissive temperatures. For both (A) and (C), hybridization of an oligonucleotide to the 18S ribosomal RNA is shown as a loading control.
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complexes are functional and can activate their downstream
effectors in v-Rel transformed cells, the effect of stimulating and
inhibiting the TGF-β pathway in CEFs infected with retroviruses
expressing v-Rel or with CSV control virus was evaluated. Cells were
treated for 30 min with recombinant TGF-β2 ligand only, treated for
6 h with the SB-431542 inhibitor of the TGF-β type I receptor (TβIR)
followed by a 30 min treatment with TGF-β2, or left untreated. To
determine whether TGF-β receptor activity was stimulated by
ligand treatment or blocked by kinase inhibitor treatment, the
phosphorylated levels of the downstream target, Smad3, were
analyzed by Western blot. In both v-Rel-expressing and control
cells, TGF-β2 treatment resulted in increased levels of phosphory-
lated Smad3 relative to untreated cells whereas inhibitor treatment
dramatically decreased TGF-β2-mediated phosphorylation of
Smad3 (Fig. 3A). These effects were most notable in cells
transformed by v-Rel, possibly due to the higher levels of TβIIR
present on their surface (Fig. 2B). v-Rel transformed cells also
activate Smad3 more rapidly compared to control cells, as
demonstrated in dose-dependent TGF-β2 treatments (Fig. S2A).
Together, these results suggest that the TGF-β pathway is functional
and can be effectively stimulated by its ligand or blocked by a kinase
inhibitor in v-Rel transformed cells. Reporter assays were alsoFig. 2. Increased protein levels of TGF-β/Smad signaling components in v-Rel transformed c
(left panel) and CEFs (right panel) over a time course of 10–14 days following infection with
three–four days from DT40 cells once they reached a density of at least 3×106 cells/ml and
results from one of three experiments are shown. (B) Whole cell lysates (40 μg) prepared fr
infected with CSV (H) were analyzed by Western blot for the expression of TβIIR, total andperformed in CEFs infected with retroviruses expressing v-Rel and
CSV to compare the relative activity of the TGF-β pathway and its
downstream activation of Smad3. v-Rel efﬁciently induced the
activity of luciferase reporter constructs containing tandem Smad3-
binding sites by at least two-fold over CSV control cells (Fig. 3B).
Furthermore, upon TGF-β2 treatment, both control and v-Rel
transformed cells revealed increased luciferase activity compared
to carrier-treated samples. Consistent with the results of Fig. 3A,
ligand treatment led to a slightly greater transactivation of the
reporter construct in v-Rel transformed cells relative to control cells.
These results indicate that v-Rel may directly activate Smad3 and/or
activate the TGF-β pathway which can lead to the activation of
Smad3.
Inhibiting TGF-β signaling suppresses colony formation in v-Rel
transformed cells
To analyze the importance of elevated levels of TGF-β signaling in
v-Rel-transformed cells, experiments were performed to examine the
effect of blocking TGF-β signaling. Three histologically distinct v-Rel
transformed lymphoid cell lines (160/2T cell line, 123/12 B cell line,
and 123/6T non-B/non-T cell line) were treated with the SB-431542
TβIR inhibitor or with DMSO carrier followed by preparation of wholeells. (A) ELISAs were performed to analyze the levels of TGF-β2 secreted by DT40 cells
retroviruses expressing c-Rel, v-Rel, or with CSV helper virus. Media was collected every
every two–three days from CEF cultures once they became conﬂuent. Representative
om DT40 cells and CEFs infected with retroviruses expressing c-Rel (C) or v-Rel (V) or
phosphorylated Smad2, and total and phosphorylated Smad3.
Fig. 3. Activation of Smad3 in v-Rel transformed cells. (A) CEFs infectedwith viruses expressing v-Rel (V) orwith CSVhelper virus (H)were left untreated, treatedwith 2 ng/ml TGF-β2 for
30 min, or treatedwith3 μMTβIR inhibitor for 6 h followedby30 min treatmentwith2 ng/mlTGF-β2.Whole cell lysatesprepared fromthese cellswere analyzed for theexpressionof total
and phosphorylated Smad3 byWestern blot. (B) CEFs infectedwith retroviruses expressing v-Rel or CSV (control) were transiently transfectedwith a reporter vector containing tandem
Smad3binding sites. At 32 hpost-transfection, lysateswereprepared fromcells treatedwith 2 ng/mlTGF-β2or carrier for themeasurement of luciferase activity. The averageand standard
error of three experiments is shown (*Pb0.05).
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remained constant, phospho-Smad3 expression was reduced in all
three cell lines treated with the inhibitor compared to the DMSO
control (Fig. 4A). Cell counts over a two day time course did not reveal
signiﬁcant differences in growth or cell death between inhibitor-
treated and carrier-treated cells for each cell line (data not shown).
Uninfected DT40 cells were also treated with the TβIR inhibitor to
assess its effect on non-v-Rel transformed cells. Unlike the v-Rel cell
lines, uninfected DT40 cells have signiﬁcantly lower levels of Smad3.
Thus, a reduction in phospho-Smad3 levels in inhibitor-treated DT40
cells was observed only after a longer exposure (Fig. S2B). The
expression of total and phospho-Smad2was also analyzed in the three
v-Rel transformed cell lines treated with or without the inhibitor. In
accordance with results of Fig. 2B where phospho-Smad2 levels are
slightly increased in v-Rel transformed cells, inhibitor treatment had
the opposite effect of reducing the levels of phospho-Smad2 (Fig. 4A).
This is not surprising as Smad2 is also a downstream effector of TGF-β
signaling and can be activated by these receptors.
The effect of the SB-431542 TβIR inhibitor on v-Rel transformation
was then evaluated. The three different v-Rel transformed cell lines
were treated with the inhibitor, plated in soft agar, and scored for
colony formation after 10 days. In the T cells (160/2), inhibitor
treatment reduced colony growth in soft agar by 97% compared to
DMSO carrier (Fig. 4B).With the B cell line (123/12), colony formation
was inhibited by almost 50% whereas in the non-B/non-T cells (123/
6T), an 80% reduction in colony formation was observed with
inhibitor treatment relative to control. Together, these results suggest
that blocking the activity of TβIR strongly suppresses the transformed
phenotype of v-Rel-expressing cells. The transformation potential of
non-v-Rel transformed DT40 cells treated with the TβIR inhibitor was
also tested. No signiﬁcant difference was observed in colony
formation in these cells compared to carrier-treated samples
(Fig. 4B), suggesting that reduction in colony formation is not a
general effect of the inhibitor.
While receptor-activated Smads are the major effectors of TGF-β
signaling, other pathways have been shown to be activated in certain
contexts and cell types, particularlyMAPKpathways (Arsura et al., 2003;
Derynck and Zhang, 2003; Javelaud and Mauviel, 2005). Therefore,
changes in MAPK signaling were also evaluated in SB-431542 TβIR
inhibitor-treated cells. We have previously observed elevated levels of
phosphorylated ERK and JNK in v-Rel transformed cells (Kralova et al.,
2010). Treatment of v-Rel transformed DT40 cells with the TβIRinhibitor did not reveal differences in the activation of the ERK, JNK, and
p38MAPK signaling pathways (Fig. S2C). These results suggest that the
reduction in v-Rel colony formation is mainly dependent on Smad
activation.
To corroborate the results of the colony assays performed with
the SB-431542 TβIR inhibitor, the effect of blocking TGF-β
signaling on v-Rel transformation was also tested using a different
TβIR inhibitor, SB-525334 (Grygielko et al., 2005). The 160/2 v-Rel
transformed cell line was treated with the SB-525334 inhibitor or
DMSO carrier, plated in soft agar, and scored for colony formation.
This inhibitor produced approximately an 80% decrease in colony
formation, an effect similar to that observed with the SB-431542
inhibitor (Fig. 4C). Inhibitor-treated 160/2 cells revealed a
corresponding reduction in the levels of phosphorylated Smad3
with no changes in the levels of total Smad3. Uninfected DT40 cells
treated with the same inhibitor did not reveal signiﬁcant
differences in colony numbers when compared to DMSO carrier-
treated cells.
TGF-β signaling is important in the initiation of v-Rel transformation
The experiments described above analyzed the role of TGF-β
signaling in cells stably transformed by v-Rel. To determine
whether TGF-β signaling is involved in the initial stages of v-Rel
transformation, primary splenic lymphocytes were analyzed for
their ability to form colonies in soft agar after TβIR inhibitor
treatment. Primary splenic lymphocytes were harvested from
three-week old chickens and infected with retroviruses expressing
v-Rel. The next day, cells were treated with 1, 3, and 5 μM of the
SB-431542 TβIR inhibitor followed by preparation of whole cell
lysates for Western blot analysis. A dose-dependent decrease in
the levels of phosphorylated Smad3 was observed with no change
in total Smad3 levels (Fig. 5A). Cells were also plated in soft agar
after inhibitor treatment and colonies scored 10 days later.
Primary splenic lymphocytes infected with the CSV control virus
are not transformed, and therefore did not form colonies in soft
agar (data not shown). The colony-forming ability of primary
splenic lymphocytes expressing v-Rel was reduced with increasing
concentrations of the inhibitor (Fig. 5B). While 3 μM inhibitor
treatment led to approximately a 40% decrease in colony numbers
compared to control DMSO-treated cells, 5 μM inhibitor treatment
produced the most dramatic reduction in colony formation (70%).
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infected with retroviruses expressing v-Rel were treated with
increasing concentrations of TGF-β2. Whole cell extracts were
prepared from these cells, and the expression of total and phospho-
Smad3was analyzed byWestern blot. Ligand treatment augmented
the levels of phospho-Smad3 in a dose-dependent manner while
total Smad3 levels remained constant in all samples (Fig. 5C).
Following exposure to increasing concentrations of TGF-β2,
primary splenic lymphocytes expressing v-Rel were also plated in
soft agar. TGF-β2 treatment at 0.2 ng/ml enhanced colony forma-
tion by two-fold compared to carrier-treated cells (Fig. 5D).
Interestingly, at higher doses (0.8 ng/ml), TGF-β2 elicited a
negative effect on the ability of primary splenic lymphocytes to
form colonies in soft agar.
Experiments were also performed to determine whether TGF-β2
can enhance the weak transformation potential of c-Rel. Primary
splenic lymphocytes were infected with CSV and the REV C retrovirus,
treated with 0.5 ng/ml TGF-β2, and analyzed for transformation
potential through liquid transformation assays (since c-Rel trans-
formed cells do not form colonies in soft agar). Treatment with TGF-
β2 ligand did not lead to a signiﬁcant increase in the ability of c-Rel to
transform splenic lymphocytes in liquid culture (Fig. S3B). Overall,
these experiments indicate that TGF-β signaling is important in the
initiation of v-Rel transformation and plays a more important role in
the oncogenic potential of v-Rel over that of c-Rel.Fig. 4. Effects of inhibiting TGF-β signaling activity in v-Rel transformed cells. (A) Three hist
6 h with 3 μM SB-431542 TβIR inhibitor (lanes 2, 4, and 6) or carrier DMSO (lanes 1, 3, and 5
blot for the expression of total and phosphorylated Smad3, total and phosphorylated Smad2
DT40 cells were plated in soft agar and scored for colony formation after 7–10 days. The num
line. The number of colonies formed by the SB-431542 TβIR inhibitor-treated cells was norm
were treated with 3 μM SB-525334 TβIR inhibitor or DMSO carrier for 6 h before plating in so
for the expression of total and phosporylated Smad3 by Western blot, shown in the inset. Th
DMSO-treated samples for each cell type and is represented here. For (B) and (C), the averInhibiting the activity or expression of Smad3 reduces the transforming
ability of v-Rel
The results above revealed the importance of Smad proteins in
relaying TGF-β signaling (Figs. 3 and 4). To gain additional insight into
the contribution of elevated levels of Smad proteins, particularly
Smad3, in v-Rel transformation, experiments were performed to
examine the effects of reducing Smad3 activity. Mutation of the serine
residues in the ‘SSXS’ domain of receptor-activated Smads has been
previously described to alter their ability to be phosphorylated by the
TβIR (Kawabata et al., 1999; Liu et al., 1997). DN Smad3 was
generated by mutating the serine residues to alanine residues,
resulting in a mutant that cannot be activated by TβIR.
To determine the effect of DN Smad3 on Smad3-dependent
transcription, luciferase reporter assays were performed. A pGL3
reporter construct containing tandem Smad3-binding sites from
the PAI-1 promoter was cotransfected into CEFs with expression
plasmids (Rc/RSV) carrying wild-type (WT) Smad3 or DN Smad3.
Cells transfected with WT Smad3 induced luciferase activity by
10-fold compared to cells transfected with the empty Rc/RSV
vector (Fig. S4A). Interestingly, DN Smad3 also induced luciferase
activity that surpassed the basal level of activity observed with
empty Rc/RSV vector. This result is consistent with the observa-
tion in certain contexts that overexpression of dominant negative
Smad proteins can lead to the activation of luciferase activity inologically distinct v-Rel transformed cell lines (160/2, 123/12, 123/6T) were treated for
) as control. Whole cell lysates were prepared from these cells and analyzed byWestern
, and Rel proteins. (B) The v-Rel transformed cell lines described in (A) and uninfected
ber of colonies formed by DMSO-treated samples was standardized to 100 for each cell
alized based on this standard and represented here. (C) 160/2 and uninfected DT40 cells
ft agar. Whole cell lysates were also prepared from the treated 160/2 cells and analyzed
e number of colonies formed by the inhibitor-treated cells was normalized against the
age and standard error of three experiments is shown (*Pb0.05, ***Pb0.001).
Fig. 5. TGF-β signaling in transformation of primary splenic lymphocytes by v-Rel. (A) REV-based retroviruses expressing v-Rel (REV-TW) were used to infect primary splenic
lymphocytes from three-week old chickens. The infected cells were treated with 1, 3, or 5 μM SB-431542 TβIR inhibitor or DMSO carrier (CT) for 6 h and then harvested for Western
blot to analyze expression of phosphorylated and total Smad3, and Rel proteins. A slightly longer exposure of the phospho-Smad3 blot is shown to demonstrate the dose-dependent
decrease in phosphorylated Smad3 levels. (B) At 24 h after infection with REV-TW, primary splenic lymphocytes were pretreated and plated in soft agar with the indicated doses of
TβIR inhibitor. Colonies were scored after 10 days. (C) Primary splenic lymphocytes infected with the REV-TW retrovirus were treated with 0.1, 0.2, 0.4, or 0.8 ng/ml TGF-β2 or
carrier (CT) for 30 min. Whole cell lysates were then prepared and analyzed byWestern blot for the expression of phosphorylated and total Smad3, and Rel proteins. (D) Cells were
pretreated and plated in soft agar with the indicated doses of TGF-β, and colonies were scored after 10 days. For both (B) and (D), colony numbers were normalized to those derived
from carrier-treated cells. The average and standard error of three experiments is shown (*Pb0.05, **Pb0.01, ***Pb0.001).
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1997; Zhang et al., 1996). Upon TGF-β2 treatment, cells trans-
fected with the empty Rc/RSV expression vector demonstrated an
almost seven-fold increase in luciferase activity, suggesting a
functional endogenous Smad transcriptional response (Fig. S4A).
WT Smad3 also exhibited a robust response to TGF-β2 whereas
DN Smad3 exhibited little to no response relative to carrier-
treated samples. Western blot analysis of whole cell lysates
prepared from cells used in the reporter assays conﬁrmed the
appropriate expression of WT and DN Smad3 (Fig. S4B). The levels
of phospho-Smad3 were equivalent among all samples treated
with the carrier solution. In response to TGF-β2, phospho-Smad3
levels increased in cells transfected with empty Rc/RSV vector and
did so even more dramatically in WT Smad3-expressing cells.
TGF-β2 exposure failed to signiﬁcantly induce Smad3 phosphor-
ylation in DN Smad3-expressing cells over that of carrier-treated
samples.
Once the appropriate activity of the Smad3 mutants was
conﬁrmed, experiments were performed to assess the effects of
their overexpression in v-Rel transformed cells. RSV-based retroviral
vectors (DS) constructed to express WT or DN Smad3 were used to
infect v-Rel transformed cell lines. Whole cell lysates were prepared
from these infected cells and analyzed byWestern blot. In all three cell
lines, WT and DN Smad3 were overexpressed above the endogenous
Smad3 levels observed in the DS vector control samples (Fig. 6A). Cells
overexpressing WT Smad3 had higher levels of phosphorylated
Smad3 compared to DS control. Phospho-Smad3 expression was
decreased in cells overexpressing DN Smad3 compared to thoseoverexpressing WT Smad3, indicating the reduced ability of the
dominant negative mutant to be activated by the TGF-β receptor.
The Smad3-encoding viruses were then evaluated for their ability to
alter the transformed phenotype of the v-Rel transformed cell lines.
Cells were plated in soft agar after infection with the retroviruses and
then scored for colony formation after 10 days. The overexpression of
WT Smad3 promoted colony formation by almost two fold compared to
DSempty vector control in 160/2 cells (Fig. 6B).While this effectwasnot
as dramatic in 123/12 and 123/6T cells, ectopic expression ofWT Smad3
still produced a 1.5-fold increase (Pb0.05) in colony formation over that
of control samples. In contrast, all three cell lines infected with
retroviruses expressing DN Smad3 exhibited approximately a 50%
reduction in colony numbers.
In complementary experiments, the effect of reducing endogenous
levels of Smad3 on v-Rel transformation was analyzed. Retroviral
vectorswere constructed to express shRNAs that targeted smad3 aswell
as smad2, to determine the extent of its involvement in v-Rel
transformation. The ability of a speciﬁc shRNA to effectively reduce
the levels of its endogenous target was evaluated in 160/2 cells. Cells
were infected with empty viruses (RCAS), viruses encoding shRNAs
speciﬁc for smad3 and smad2, or an shRNA speciﬁc for luciferase (luc) as
a negative control. The expression of Smad3 and Smad2was reduced by
20–40% in cells expressing the speciﬁc shRNAs relative to cells infected
with the control RCAS and luc shRNAs (Fig. 6C). Luciferase assays of CEFs
infected with shRNAs speciﬁc to smad3 were also performed using a
Smad3-speciﬁc reporter vector. The results demonstrated approxi-
mately a 50% reduction in luciferase activity in Smad3 shRNA-infected
cells compared to those infected with the RCAS control (Fig. 6D),
Fig. 6. Effect of altered Smad3 activity and expression on v-Rel transformation. (A) v-Rel transformed cell lines (160/2, 123/12, and 123/6T) were infected with control DS virus (CT)
or with one expressing WT or DN Smad3. Whole cell lysates were prepared from these cells and analyzed by Western blot for the ectopic expression of Smad3, phosphorylated
Smad3, and Rel proteins. (B) The v-Rel transformed cell lines described in (A) were plated in soft agar eight days post-infection and scored for colony formation after 7–10 days. The
number of colonies formed by control DS-infected cells was standardized to 100 for each cell line. The number of colonies formed by cells infected with retroviruses expressingWT or
DN Smad3 was normalized based on this standard. The average and standard error of three experiments is shown (*Pb0.5, **Pb0.01, ***Pb0.001). (C) Empty RCAS retroviruses (R)
or RCAS viruses expressing an shRNA speciﬁc to luciferase (Luc), smad3, or smad2 were used to infect 160/2 cells. Whole cell lysates from infected cells were harvested eight days
after infection and analyzed by Western blot for the expression of Smad3 or Smad2. The extent of upregulation of each Smad protein was quantitated and is indicated below the
corresponding Western blot. (D) Luciferase reporter assays were performed in CEFs about 7–8 days post-infection with the smad3 shRNAs. Cells were transiently transfected with a
Smad-responsive reporter and treated with TGF-β2 about 30 min prior to harvest. At 32 h post-transfection, lysates were prepared from cells for the measurement of luciferase
activity. Fold activation was calculated in reference to baseline activity of cells infected with the empty RCAS retroviral vector. The average and standard error of three experiments is
shown (**Pb0.01). (E) The RCAS-infected 160/2 cells described above were also plated in soft agar and scored for colony formation after eight days. The number of colonies from
each experiment was normalized to control RCAS-infected cells. The average and standard error of four experiments is shown (*Pb0.5, **Pb0.01).
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The shRNA-encoding retroviruses were then evaluated for their
ability to alter the transformed phenotype of 160/2 cells. Cells infected
with viruses encoding the luc shRNA had no effect on colony
formation. Viruses encoding shRNAs speciﬁc for smad3 reduced the
ability of these cells to form colonies in soft agar by approximately 50%
relative to cells infected with empty control virus (Fig. 6E), correlating
with the effect of DN Smad3 on the transforming ability of v-Rel. In
agreement with the RNA and protein expression analyses, shRNAs
against smad2 did not lead to signiﬁcant effects on the transformation
potential of v-Rel. Taken together, these colony formation assays
indicate that TGF-β-activated Smad3 is an important mediator of the
v-Rel transformation process.
Discussion
Certain oncogenes have been found to activate TGF-β signaling to
obtain an advantage over normal cells for tumor growth and invasion
(Janda et al., 2002; Muraoka et al., 2003; Wang et al., 2010). Here, wereport that v-Rel activates key components of the TGF-β/Smad
signaling pathway, which contributes to its oncogenicity. The
expression of tgf-β2, tgf-β3, tgfbr2, and smad3 RNA was increased in
v-Rel transformed ﬁbroblasts and lymphoid cells relative to control
cells (Fig. 1). The protein levels of TGF-β2, TβIIR, and the total and
phosphorylated levels of Smad3 were also elevated in these cells
(Fig. 2). Furthermore, TGF-β2 and activation of Smad3 were shown to
be important for v-Rel colony formation. In comparison to v-Rel, the
weakly oncogenic c-Rel had only a small to moderate effect on the
expression and activity of TGF-β and Smad signaling components and
did not require the activation of this pathway for its ability to induce
transformation. Overall, differences in the expression of TGF-β and
Smad family members between cells expressing c-Rel and v-Rel may
contribute to the enhanced oncogenicity of v-Rel relative to c-Rel.
v-Rel transformed cells are unique in their requirement for the
activation of TGF-β signaling for maintaining their transformed
phenotype. Unlike DT40 cells, v-Rel transformed cell lines exposed
to the TβIR inhibitors demonstrated a dramatic reduction in colony
formation (Fig. 4). These results are consistent with previous reports
that have demonstrated impaired growth of various tumor cells
68 R. Tiwari et al. / Virology 413 (2011) 60–71treated with the SB-431542 inhibitor (Halder et al., 2005; Hjelmeland
et al., 2004; Matsuyama et al., 2003). Human osteosarcoma, malignant
glioma, human breast cancer, pancreatic adenocarcinoma, and colon
cancer cells have been shown to be sensitive to the effects of this TβIR
inhibitor due to its ability to block the tumor-promoting effects of
TGF-β. However, genes that contribute to the maintenance of v-Rel
transformation may be distinct from those involved in the initial
stages of transformation. Likewise, the role of TGF-β signaling may
vary depending on the context and stage of transformation. Studies
with v-Rel enable the analysis of genes which contribute to the
beginning stages of transformation. The exposure of primary splenic
lymphocytes expressing v-Rel to the SB-431542 TβIR inhibitor
indicated that TGF-β signaling is also important in the initiation of
v-Rel transformation (Fig. 5).
In complementary experiments, recombinant TGF-β2 enhanced
colony formation in theprimary splenocytes expressingv-Rel. However,
this effect was dose-dependent as higher TGF-β2 concentrations had a
negative impact on v-Rel transformation. A similar inhibitory effect on
colony formation was observed when 160/2 v-Rel transformed cells
were treated with increasing concentrations of TGF-β2, suggesting that
this result is not cell type-speciﬁc or transformation stage-dependent
(data not shown). This opposing, biphasic effect of TGF-β is not without
precedent. For instance, TGF-β2 has been shown to stimulate osteoclast
differentiation and proliferation of murine hematopoietic stem cells at
lowconcentrations but block this process at higher doses (Henckaerts et
al., 2004; Karst et al., 2004). Vaidya et al. also reported a similar
bidirectional effect of TGF-β1 on hematopoietic cell proliferation and
attributed this phenomenon to the differential activation of pathways
by TGF-β1 (Kale and Vaidya, 2004). Based on our results and those from
other studies, it appears that certain pathways may be modulated by
subtle changes in TGF-β concentration, which may inﬂuence the
outcome of TGF-β responses. Precisely which pathways mediate the
pro-oncogenic responses of TGF-β in v-Rel transformed cells andwhich
evoke tumor-suppressive effects is not clear.
Many TGF-β-inducible pro-oncogenic pathways function indepen-
dently of Smads or require cooperation between Smads and other
pathways under transforming conditions (Derynck and Zhang, 2003;
Moustakas and Heldin, 2005). Signaling by the MAPK pathways was not
altered in v-Rel transformed cells treated with the TβIR inhibitor,
indicating that this alternative pathway is not activated in response to
TGF-β. Although we cannot rule out the possibility that TGF-β activates
other pathways in v-Rel transformed cells, Smad3 appears to be the
principal effector protein (Figs. 3 and 4). Furthermore, our results reveal
the importance of active, phosphorylated Smad3 in mediating TGF-β
responses to ultimately support v-Rel transformation. The relatively
higher levels of TGF-β2 produced by v-Rel transformed cells are likely to
stimulate TGF-β signaling in an autocrine and paracrine manner (Fig. 2).
Thus, WT Smad3 can be phosphorylated and continually activated in a
physiological manner, leading to enhanced v-Rel transformation poten-
tial whereas DN Smad3 is unable to promote colony formation (Fig. 6).
The role of Smad3 in oncogenesis is not clearly deﬁned. Several
studies support a tumor suppressive role for Smad3 in cancer. For
instance, reduced expression of Smad3 has been detected in human
gastric tumors and skin carcinogenesis and has been shown to promote
myeloid leukemia (Han et al., 2004; He et al., 2001; Kurokawa et al.,
1998; Sood et al., 1999). Our studies suggest a pro-oncogenic role for
Smad3, whereby the increased expression and TGF-β-dependent
activation of Smad3 promotes v-Rel transformation. Interestingly,
while the expression of total Smad2 was unchanged (Figs.1 and 2),
increased levels of TGF-β ligand and receptor in v-Rel transformed cells
were likely sources of higher levels of phosphorylated Smad2. Despite
this, Smad2 did not appear to play an important role in v-Rel
transformation (Fig. 6). Other studies have also reported differing and
complex roles of the Smad proteins in cancer. For instance, a recent
study demonstrated tumor-promoting and metastatic activities of
Smad3 in breast cancer whereas Smad2 played a tumor-suppressorrole (Petersen et al., 2009). Overall, results from various studies,
including ours, demonstrate that Smad2 and Smad3 may be selectively
activated and may play different roles in different types of cancer.
Some studies have reported that deﬁcient TGF-β/Smad signaling is
important in the progression of head and neck cancers and B-chronic
lymphocytic leukemia that are characterized by constitutive Rel/NF-κB
activation (Cohen et al., 2009; Zaninoni et al., 2003). However, our
results provide evidence for the activation of TGF-β/Smad signaling as
an important player in v-Rel transformation. v-Rel has likely employed
TGF-β signaling mediated by Smad3 to selectively activate genes that
promote the transformation process. Moreover, genes encoding for the
adhesion receptor CD44 and integrin β8 are upregulated in v-Rel
transformed cells in ourmicroarrays (manuscript in preparation). These
genes have also been identiﬁed as TGF-β/Smad targets by other groups
and are particularly interesting as they are implicated in the pathogen-
esis of malignancies caused by aberrant Rel/NF-κB activity (Margadant
and Sonnenberg, 2010; Robetorye et al., 2002; Tzankov et al., 2003;
Verrecchia et al., 2001). Studies to determine whether upregulated
expression of such genes is TGF-β/Smad-dependent in v-Rel trans-
formed cells would provide further insight into the importance of TGF-
β/Smad signaling in Rel/NF-κB oncogenesis.
Materials and methods
Primary chicken embryonic ﬁbroblasts (CEFs)were prepared from 10
to 11 day-old embryos (Charles River SPAFAS, Wilmington, MA) and
grown in Dulbecco's modiﬁed Eagle's Medium (DMEM) supplemented
with 5% fetal calf serum (FCS), 5% chicken serum (CS), and 1% Antibiotic–
Antimycotic reagent (Invitrogen Life Technologies, Carlsbad, CA) at 37 °C
with 8% CO2. The following avian cell lines used in this study were also
maintained in the same conditions: B-cell lines transformed by avian
leukosis virus (DT40 and DT95), a T-cell line transformed by Marek's
disease virus (RP1), a macrophage-like cell line transformed by avian
myeloblastosis virus (BM2), a macrophage cell line transformed by
myelocytomatosis virus (HD11), andanerythroid cell line transformedby
the avian erythroblastosis virus (AEV). The v-Rel-transformed cell lines
include a T-cell line (160/2), a B-cell line (123/12), a non-B/non-T cell line
(123/6T) (Hrdlickova et al., 1994), a mixed population lymphocytic cell
line (C4-1), and a temperature-sensitive v-Rel cell line (White and
Gilmore, 1993).
Cloning and mutagenesis of Smad3
Full length avian Smad3 was ampliﬁed by RT-PCR from cDNA
derived from chicken brain tissue using the GC-melt cDNA Advantage
Kit (BD Clontech Biosciences, Mountain View, CA). The primers were
designed from sequences ﬂanking the avian Smad3 coding region and
are as follows: Smad3 Forward 5′-GAATTGACGTCGATATCGGCA-
GAGCCAGCATGTCCTCCATCCTGC-3′ and Smad3 Reverse 5′-
CTTAAGCGGCCGCGATATCCCTTAGGAGACGCTGGAGCA-3′. PCR-ampli-
ﬁed Smad3 was then inserted into the pGEM-T easy vector (Promega
Corporation, Madison, WI), generating pGEM-WT-Smad3. To gener-
ate the dominant negative (DN) Smad3mutant, point mutations were
introduced to sequences in pGEM-WT-Smad3 encoding the SSXS
domain in the C-terminal region of the protein using the Quik-Change
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The primers
designed were as follows: 5′-GAGCATCCGCTGCgccgcaGTCgcaTAAGG-
GATATCGC-3′. Lower case letters indicate position of the mutagenic
nucleotides. The sequences of the PCR-ampliﬁed wild-type (WT) and
mutagenized DN smad3 were conﬁrmed by the DNA Sequencing
Facility at the University of Texas at Austin.
Retroviral vectors and preparation of virus stocks
Three different retroviral vector systems were employed in these
studies. The REV-based retroviral vectors, pREV-C and pREV-TW, contain
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The DS-based retroviruses were constructed by cloning wild-type and
DN smad3 into the pTZDS-XB vector (containing the 3′portion of env and
one LTR) within the XhoI/BssHII sites (Hrdlickova et al., 2001). The Rous
sarcoma virus (RSV)-based shRNA vector system is composed of
pRFPRNAiC and RCASARNAi (Das et al., 2006). Gene speciﬁc oligonucleo-
tides were ﬁrst cloned into pRFPRNAiC. A NotI–ClaI restriction fragment
containing this cassette downstream of the chicken U6 promoter was
excised and cloned into RCASARNAi to generate a retroviral vector
expressing each shRNA. The oligos encoding the shRNA hairpins for each
gene are described in Supplementary Materials and Methods.
Retroviral stock preparation has been previously described (Liss
and Bose, 2002). Brieﬂy, primary CEFs were plated at a density of
6×105 cells/60 mm tissue culture plate 24 h prior to transfection. For
generationof REV-based retroviral stocks, 10 μg of pREV retroviral DNA
together with 0.3 μg of pCSV11S3 (encoding the chicken syncytial
helper virus) was mixed with 0.25 M CaCl2 and an equal volume of
BES-buffered saline solution. Viral supernatant ﬂuids were harvested
10–14 days after transfection and stored at −80 °C. RCASARNAi
retroviral constructs were transfected as described above but without
pCSV11S3. DS retroviral stockswere prepared by linearizing pTZDS-XB
by digestion with SalI and ligating to the SalI-digested pREP-B vector
(containing one LTR, gag, pol, and the 5′ portion of env). The ligated
DNAs (4 μg)were then directly used for transfection of CEFs. Retroviral
stocks were harvested 6–7 days post-transfection before −80 °C
storage.
To quantitate the viral stocks, virus aliquots were added to a
Hybond N+ nylon membrane (Amersham Biosciences, Piscataway,
NJ) using a dot–blot transfer unit. For controls, stocks of viruses with
titers previously determined by immunohistochemical assays were
used (Liss and Bose, 2002). Membranes were dried and crosslinked
with UV. Pre-hybridization of the membranes was carried out at 55 °C
using the UltraHyb solution (Ambion, Austin, TX) after which
radiolabeled probe was added (4×106 cpm/ml). Probes for the DS
viruses were randomly labeled with [32P]dCTP (DECAprime II Kit,
Ambion), while those for the REV-based viruses were labeled with
[32P]dATP. The hybridized probe was detected the next day using the
ImageQuant software, and titers were normalized to known titers of
the control virus.
Western blot analysis
Proteins from whole cell lysates were resolved by 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
electrophoretically transferred to Optitran nitrocellulose membranes
(Schleicher and Schuell, Keene, NH). Equal loading of lysates was
analyzed by staining with Ponceau S. Primary antibodies used were as
follows: Smad3 (Millipore, Billerica, MA), phosphorylated Smad3
(R&D Systems, Minneapolis, MN), TβIIR (Abcam, Cambridge, MA),
Smad2 and phosphorylated Smad2 (Cell Signaling Technology,
Boston, MA). A monoclonal antibody HY87 was used for the detection
of v-Rel (Hrdlickova et al., 1994). Secondary antibodies employed for
this study were horseradish peroxidase-conjugated donkey anti-
rabbit IgG, donkey anti-mouse IgG, and donkey anti-sheep IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA). Protein
expression was visualized by Western lighting chemiluminescence
reagent (Perkin-Elmer Life and Analytical Sciences, Wellesley, MA).
Northern blot analysis
Total RNA was prepared from the TriReagent (Ambion), according
to the manufacturer's instructions. Northern blots were performed as
previously described (Majid et al., 2006). Brieﬂy, 10 μg of each sample
was separated by electrophoresis on a 1% agarose-formaldehyde gel.
RNA transfer was performed overnight onto a Hybond N+ nylon
membrane (Amersham Biosciences). The membrane was then dried,and RNA was crosslinked with UV. Equal loading and transfer of RNA
was conﬁrmed by methylene blue staining. Membranes were
prehybridized at 55 °C using UltraHyb solution (Ambion) followed
by addition of radiolabeled probes (4×106 cpm/ml). Random priming
with [32P]dCTP was used to label the probes (DECAprime II Kit,
Ambion). cDNAs for generating probes were obtained from the BBSRC
ChickEST Database and are listed as follows: tgf-β1 (ChEST673K20),
tg f-β2 (ChEST539M16) , tg f -β3 (ChEST967G20), tg fbr1
(ChEST507H10), tgfbr2 (ChEST863E11), smad2 (ChEST261L19),
smad3 (ChEST768O18), and smad4 (ChEST747A11).
Real-time PCR
RNA (60 ng) prepared from CEFs and DT40 cells described above
was reverse-transcribed into cDNA using the Superscript First Strand
Synthesis System (Invitrogen Life Technologies). The synthesized
cDNA was combined with Smad2, Smad3, or TGF-β2-speciﬁc primers
or GAPDH primers as control, TaqMan MGB probes speciﬁc for each
gene (Applied Biosystems), and FastStart Universal Probe Master Mix
(Roche, Indianapolis, IN). PCR reactions were performed using
standard 96-well plates in the ABI 7900HT Sequence Detection
System using 40 cycles of 94 °C for 15 s and 60 °C for 1 min. Cycle
threshold (Ct) values were obtained for each sample run in three
wells, and the averages and standard deviations were calculated. To
normalize the smad2, smad3, and tgf-β2 samples, the ΔCt values were
calculated by subtracting the Ct value of each sample from the Ct of
GAPDH. The ΔΔCt values were gathered by subtracting the ΔCt values
of each sample from that of the CSV control sample. Relative mRNA
expression levels of each gene were then obtained by 2−ΔΔCt
calculations. The normalized relative expression levels of each gene
are the result of three experiments.
Plasmid construction and luciferase reporter assays
The pGL3–6×SBS reporter vector used in the luciferase assays
contains six tandem TGF-β-inducible Smad3-binding sites (SBS).
Oligonucleotides containing the 6×SBS binding site with ﬂanking
KpnI and MluI restriction sites were designed as follows: 6×SBS top
5′-CAGCCAGACAAAAAGCCAGACATTTAGCCAGACAGAGCTCAGCCA-
GACAAAAAGCCAGACATTTAGCCAGACAA-3′; 6×SBS bottom 5′-
C T G T C T G G C T A A A T G T C T G G C T T T T T G T C T G G C T G G -
TACCGCGTTGTCTGGCTAAATGTCTGGCTTTTTGTCTGGCTGAGCT-3′. By
annealing these complementary oligonucleotides, the 6×SBS binding
site was created and cloned into the pGL3 reporter vector (Promega).
For construction of expression vectors, wild-type and DN smad3
fragments were excised from the pGEM-T easy vector by digestion
with EcoRV. The gene fragments were then cloned in-frame into the
pRc/RSV expression vector (Invitrogen Life Technologies) digested
with HindIII and blunted for 5′ overhangs.
Reporter assays were performed as previously described (Majid et
al., 2006). Brieﬂy, CEF cultures were seeded at a density of 6×105 cells/
60 mmtissue culture plate 24 h prior to transfection. DNA transfections
were carried out with 0.25 μg pRL-TK, 0.2 μg pGL3–6×SBS reporter
vector, 0.5 μg empty pRc/RSV expression vector or one containing the
wild-type or DN smad3 genes. The pBluescript SK+ plasmid was used
to maintain a total DNA concentration of 10 μg. The DNA was mixed
with 2.5 M CaCl2 and an equal volume of 2× HEPES-buffered saline
solution (HBSS). Eight hours later, cells were treated with glycerol
shock solution (15% glycerol, 2× HBSS). After an additional 24 h, cells
were harvested and luciferase activity measured using the Dual
Luciferase Reporter Assay System, according to the manufacturer's
instructions (Promega Corporation). To measure luciferase activity in
response to TGF-β, cells were treated with 2 ng/ml TGF-β2 (R&D
Systems) for 30–45 min prior to harvest at 32 h post-transfection. For
experiments in CEFs infected with RCAS retroviruses expressing
shRNAs, cells were transfected with 500 ng of the Negative Control
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Kit (SABiosciences, Frederick, MA). Glycerol shock and TGF-β2
treatment prior to harvest was performed as described above. For all
assays, luciferase activity was normalized to values of transfection
efﬁciency derived from the pRL-TK vector. The adjusted luciferase
activity obtained for cells transfected with the empty pRc/RSV vector
was considered baseline activity, and the fold induction was deter-
mined by reference to this baseline. For experimentswith CEFs infected
with retroviruses expressing v-Rel or CSV, the adjusted luciferase
activity obtained from CSV-infected cells was considered baseline. For
experiments with CEFs infected with RCAS retroviral vectors expres-
sing shRNAs, the luciferase activity from the Smad-responsive reporter
for each samplewasnormalized to that of theNegative Control reporter
and then compared against the baseline activity of the empty RCAS
vector. P-values were calculated from two-tailed Student's t-test
comparing luciferase activity of the control cells to other samples.
Soft agar colony assays of cell lines
Plating of v-Rel transformed cells in soft agar has been previously
described (Majid et al., 2006). v-Rel-transformed cell lines (160/2, 123/
12, and 123/6T) were infected with empty DS vector or DS retroviruses
expressingwild-type and DN Smad3 at amultiplicity of infection (MOI)
of 7–10 for eight days before viable cells were counted and plated in
0.35% soft agar. The plating media consisted of 0.35% Noble Agar
(Becton, Dickinson and Company, Sparks, MD) and DMEM containing
5% FCS, 5% CS, and 1% Antibiotic–Antimycotic reagent. For colony assays
with the SB-431542 or SB-525334 TβIR inhibitor (Sigma-Aldrich, St
Louis, MO), cells were treated with 3 μMof the inhibitor for 6 h prior to
soft agarplating. Inaddition, 3 μMof the inhibitor orDMSOwasadded to
the plating mix. 160/2 and 123/12 were plated at a concentration of
1.5×104 and 1×104, respectively while 123/6T and DT40 cells were
plated at 5×103 cells/plate. Plates were incubated at 37 °C and 8% CO2,
and colonies were scored 7–10 days post-plating. P-values from colony
assays with infected v-Rel cell lines were calculated from two-tailed
Student's t-test comparing the transformation efﬁciency of cells infected
with empty DS vector with those infected with DS expressing WT and
DN Smad3. For colony assays performed with cells treated with the
inhibitors, P-valueswere calculated from Student's t-test comparing the
transformation efﬁciency of DMSO-treated cellswith those treatedwith
the inhibitors.
In vitro transformation assays
Primary splenic lymphocytes were isolated from three-week old
White Leghorn chickens, as previously described (Majid et al., 2006).
Lymphocytes were puriﬁed from spleens by differential gradient
centrifugation with Histopaque-1077 (Sigma-Aldrich). Viable cells
were counted and resuspended at a density of 2×108 cells/ml and
infected with REV-TW retroviruses with a minimum titer of
1×105 infectious units/ml. Cells (150 μl) were infected at an MOI of
0.01 in a total volume of 3 ml. Infections were allowed to proceed for
24 h after which cells were plated in 0.35% soft agar medium.
Experiments with TGF-β2 involved treating cells for 30 min prior to
soft agar plating while those with the SB-431542 TβIR inhibitor
involved 6 h of pre-treatment. The plating media was the same as
described above for colony assays with v-Rel-transformed cells except
that 15% FCS was used instead of 5% FCS. In addition, appropriate
concentrations of TGF-β2 or TβIR inhibitor were added to the plating
mix. For liquid transformation assays, splenic lymphocytes were
infected with CSV and the REV-C retrovirus and a day later, cells from
each infection underwent eight 1:2 serial dilutions. Dilutions for each
infection were treated with 0.5 ng/ml TGF-β2 or carrier. 200 μl of each
dilution was then aliquoted into 12 wells in a 96-well plate. For both
in vitro and liquid transformation assays, plates were kept at 37 °C and
8% CO2 and colonies scored 10 days later. Liquid transformationefﬁciency was calculated by multiplying the number of wells showing
visible growth for a speciﬁc dilution by the reciprocal of that dilution.
P-values were calculated from two-tailed Student's t-test comparing
the transformation efﬁciency of v-Rel-infected cells treated with
carrier solution to those treated with TGF-β2 or TβIR inhibitor.
TGF-β2 Enzyme-linked immunosorbent assays
CEFs andDT40cellswere infectedwithCSVorwithREV-CorREV-TW
retroviruses with aminimum titer of 1×105 infectious units/ml. For CEF
infections, cells were plated at a density of 6×105 cells/60 mm tissue
culture plate. About 24 h later, CEFswere infectedwith 4 mlof viruswith
normalized titers. DT40 infections (5×106 cells/infection) were carried
out in 5 ml of viruswith normalized titers. Over a 10–14 day time course
of infection, 0.5 mlofmediawasharvested fromCEFswhen they reached
conﬂuency and from DT40 cultures when they reached a density of at
least 3×106 cells/ml and stored at−80 °C. CEFs were passaged at a 1:3
split every2–3 dayswhereasDT40cellswere resuspendedatadensity of
1.5×106 cells/ml every 3–4 days. At the end of the time course of
infection, ELISAs were performed on the media samples using the
Quantikine Human TGF-β2 Immunoassay (R&D Systems), according to
the manufacturer's instructions.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.02.002.
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